RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I think that the RD outcome is much more dependent on the science than the regulatory beaurocracy, because the drug would only be used for a brief period, and because it protects post-op patients from a potentially lethal complication. We've seen CX-717 approved for one-time PET studies, and the short-acting CX-516 might be effective as well, and has cleared the tox hurdles. POC in April with more than one compound that could be suitable should generate some BP interest, because irrespective of whether Neuro is jumping the gun regarding the likelihood of all this, the need is there and the numbers aren't unreasonable.

I think we've been so traumatized by the last 18 months that we've come to expect unexpected bad news, and can't imagine a simple break in our favor. I think that RD is the ideal indication to introduce ampakines into the clinic. Dumb luck.